{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-000915","form_type":"8-K","ticker":"HROW","cik":"0001360214","company_name":"HARROW, INC.","filed_at":"2025-03-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.428020+00:00","generated_at":"2026-05-24T03:47:57.950997+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Harrow Q4 revenue $66.8M (+84% YoY), net income $6.8M; FY2025 guidance >$280M","bullets":["Q4 revenue $66.8M (+84% YoY); FY2024 revenue $199.6M (+53% YoY).","GAAP net income Q4 $6.8M vs loss $9.1M; Adjusted EBITDA Q4 $22.5M vs $2.6M.","IHEEZO unit demand +43% QoQ to 49,130 units; VEVYE prescriptions +44% QoQ, approaching 5% DED market share.","TRIESENCE awarded CMS transitional pass-through (April 2025-2028); five-year supply agreement with CMO; next-gen NDA by 2027.","FY2025 revenue guidance 'over $280M' (>40% YoY); cash $47.2M; met leverage ratio, avoided warrant issuance."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-000915","json":"https://secwatch.observer/filing/0001641172-25-000915.json","markdown":"https://secwatch.observer/filing/0001641172-25-000915.md","text":"https://secwatch.observer/filing/0001641172-25-000915.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1360214/000164117225000915/0001641172-25-000915-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1360214/000164117225000915/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T03:47:57.950997+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}